The results of this network meta-analysis suggested that, in terms of efficacy, PD-1 inhibitor plus chemotherapy significantly improved the OS, PFS, and ORR in patients with advanced GC/GEJC, when compared with chemotherapy as a first-line treatment. The gene discussed is PDCD1; the disease is gastric cancer.